The short answer
Treating deficiency; pharmacologic niacin is a medicine-level intervention for selected lipid disorders.
- Evidence and scope
- Established for an indicated use
This status does not grade the ingredient for every goal, outcome, or person.
- Important limitation
- Adding high-dose niacin to modern statin therapy has not generally improved cardiovascular outcomes.
- Before deciding
- High doses can cause flushing, liver injury, glucose changes, and drug interactions.
01 / PRACTICAL GUIDE
Dose, absorption, and combinations
These are indication-specific reference or studied ranges—not a personalized prescription. Start with the objective, then check the form, label, medicines, and health conditions.
Reference or studied range—not a personalized prescription. The product label or a clinician may specify a different dose.
Dose source ↗Reference or studied range—not a personalized prescription. The product label or a clinician may specify a different dose.
Dose source ↗More is not automatically better. A clinician or product label may specify a different amount.
Water-soluble or readily water-dispersible. This does not mean excess is always harmless.
Take with food; extended-release products are not interchangeable.
Avoid self-treating cholesterol with high doses; alcohol, statins, gout, diabetes, and liver disease increase risk.
Dose and use links lead to primary or official source material. Search links are discovery tools, not proof that every returned paper applies.
02 / EVIDENCE
What the research says
We keep supportive, mixed, negative, safety, and contextual findings together. The headline never replaces the underlying papers.
These are audited counts for this JIVANA collection, not search-result totals. Participants are counted once when multiple papers use the same cohort; review papers are not added again to participant totals.
Open the research timelineResearch timeline+
Entries are ordered by publication year. A study period appears only when the source reports it.
Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes
Cumulative evidence did not support cardiovascular prevention in modern secondary-prevention settings. Apparent monotherapy benefits came mainly from two older pre-statin-era trials and may not represent current care.
Study design and methods
- Design
- Systematic review and meta-analysis of 17 clinical-outcome trials
- Population
- 35,760 patients with cardiovascular disease or dyslipidemia
- Intervention
- Niacin-containing treatment versus control
- Outcome
- Cardiovascular and coronary mortality, acute coronary events, stroke, revascularization, and major adverse cardiac events
Funding or conflict note: No conflicts of interest were reported.
Niacin therapy and the risk of new-onset diabetes
Niacin increased new-onset diabetes risk by 34%; the authors estimated one additional case per 43 people treated for five years. The association was similar with and without background statins.
Study design and methods
- Design
- Meta-analysis of 11 randomized trials
- Population
- 26,340 participants without diabetes at baseline
- Intervention
- Niacin therapy versus control
- Outcome
- New-onset diabetes
Funding or conflict note: These trials substantially overlap the 2019 cardiovascular synthesis and are excluded from aggregate totals.
Effects of extended-release niacin with laropiprant in high-risk patients
Lipids improved but major vascular events did not. Serious diabetes-control problems, new diabetes, gastrointestinal, musculoskeletal, skin, infection, and bleeding events increased; the harms apply to the tested combination.
Study design and methods
- Design
- Randomized, double-blind, placebo-controlled outcome trial
- Population
- 25,673 adults with vascular disease receiving statin-based treatment
- Intervention
- Extended-release niacin 2 g plus laropiprant 40 mg/day or placebo
- Outcome
- Major vascular events, lipid markers, and serious adverse events
Funding or conflict note: Funded by Merck and others. This trial is represented in the 2019 cardiovascular synthesis and is excluded from aggregate totals.
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
HDL and triglycerides improved, but the primary cardiovascular endpoint did not. This directly illustrates why lipid-marker changes should not be presented as proven clinical benefit.
Study design and methods
- Design
- Randomized placebo-controlled outcome trial stopped for futility
- Population
- 3,414 adults with established atherosclerotic cardiovascular disease and well-controlled LDL cholesterol
- Intervention
- Extended-release niacin 1,500–2,000 mg/day or placebo on intensive statin therapy
- Outcome
- Composite cardiovascular events and lipid markers
Funding or conflict note: Funded by the U.S. National Heart, Lung, and Blood Institute and Abbott Laboratories. Represented in the 2019 synthesis.
Unscreened discovery appendix—not evidence845 candidate publicationsSearch run: Aug 21, 2026
Complete for the displayed PubMed query at the search timestamp—not for all databases or every possible synonym. Candidates can be irrelevant, duplicate the same study, or report negative findings. They are never summed as evidence or participants until screened.
03 / SOURCES
Start with the source material
The live search is for discovery only. Search-result counts change and are not included in the audited totals above.
Recent PubMed discovery recordsDirect links to the first 12 records returned by the reproducible search. These are discovery candidates—not reviewed summaries or a count of supportive findings.
- Human-milk vitamin B-3 (niacin and vitamer) concentrations: secondary analysis of a randomized, placebo-controlled trial of maternal nicotinamide supplementation in rural Tanzania.DeBoer MD, McDermid JM, Hampel D et al. · 2026 · The American journal of clinical nutrition · PMID 42309304Open on PubMed ↗
- Pellagra in Contemporary Clinical Practice (2000-2023): A Systematic Review.Litaiem N, Sboui K, Zeglaoui F · 2026 · International journal of dermatology · PMID 41876960Open on PubMed ↗
- Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysis.Kishi T, Sakuma K, Hatano M et al. · 2026 · Journal of affective disorders · PMID 41876058Open on PubMed ↗
- Blunted Niacin Skin Flushing Response in Schizophrenia: A Meta-analysis.Wang J, Wang Q, Wang D et al. · 2026 · Schizophrenia bulletin · PMID 40401804Open on PubMed ↗
- Blunted Niacin Skin Flushing Response in Mood Disorders: A Meta-Analysis of Case-Control Studies.Wang Q, Wang J, Hu X et al. · 2026 · Depression and anxiety · PMID 42137476Open on PubMed ↗
- Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression: A Randomized Clinical Trial.Yngwe H, Plavén-Sigray P, Ekman CJ et al. · 2026 · JAMA network open · PMID 42138922Open on PubMed ↗
- Impact of conventional lipid-lowering therapy on circulating levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis of randomised controlled trials.Meng L, Huang T, Guo S et al. · 2026 · Diabetes, obesity & metabolism · PMID 41656962Open on PubMed ↗
- NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.Gallagher C, Emmanuel OO · 2026 · Ageing research reviews · PMID 41655607Open on PubMed ↗
- Metabolic reprogramming of endothelial-related pathways in COVID-19 patients treated with hyperbaric oxygen therapy: a randomized clinical trial.Jermakow N, Brodaczewska K, Kot J et al. · 2026 · Scientific reports · PMID 41851311Open on PubMed ↗
- First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies.Razak A, Mahipal A, Diamond JR et al. · 2026 · Targeted oncology · PMID 41824279Open on PubMed ↗
- Niacin Modulates Immune Responses in a Phase I Dose-Escalation Clinical Trial of Newly Diagnosed Glioblastoma.Poon CC, Hagen KM, Sarkar S et al. · 2026 · Neurology(R) neuroimmunology & neuroinflammation · PMID 41632924Open on PubMed ↗
- The differential impact of three different NAD(+) boosters on circulatory NAD and microbial metabolism in humans.Christen S, Redeuil K, Goulet L et al. · 2026 · Nature metabolism · PMID 41540253Open on PubMed ↗
04 / EXPERT CONTEXT
Expert context—not evidence
Expert positions are dated context—not scientific evidence. They never raise the evidence status or become consensus by repetition.
No direct, source-verified endorsement is currently recorded. Research authorship or discussion alone is not treated as endorsement.